secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTERPACE BIOSCIENCES, INC. (IDXG)
CIK:        0001054102
Form:       8-K
Filed at:   2026-08-20T22:45:15+00:00
Accession:  0001493152-26-039530
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Interpace shareholders approve reverse split up to 1-for-10, equity plans, and director slate
--------------------------------------------------------------------------------

- Reverse stock split authorized (1:2 to 1:10 ratio, board discretion within 1 yr): 26,180,980 for, 397,262 against.
- Amended & restated certificate of incorporation approved: 24,981,181 for, 246,552 against, 3,625 abstain.
- All five director nominees elected, incl. CEO Thomas W. Burnell (25,095,783 for) and Joseph D. Keegan (24,422,783 for).
- 2026 Equity Incentive Plan approved: 24,887,762 for; 2026 Employee Stock Purchase Plan: 24,580,773 for.
- Say-on-pay passed (24,952,970 for); EisnerAmper LLP ratified as auditor (26,442,760 for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/0001493152-26-039530-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1054102/000149315226039530/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-039530

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer